Clinical and pathologic features of secondary acute promyelocytic leukemia

American Journal of Clinical Pathology

Volumn 137, Issue 3, 2012, Pages 395-402

  Duffield, Amy S ^a   Aoki, Joseph ^a   Levis, Mark ^a   Cowan, Kathleen ^a   Gocke, Christopher D ^a   Burns, Kathleen H ^a   Borowitz, Michael J ^a   Vuica Ross, Milena ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Acute myeloid leukemia with myelodysplasia related changes; Acute promyelocytic leukemia; APL; Flow cytometry; Therapy related acute myeloid leukemia; Therapy related myeloid neoplasm

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; GYRASE INHIBITOR; TAMOXIFEN; TRASTUZUMAB; VASCULOTROPIN RECEPTOR 1; LEUKOCYTE ANTIGEN; PROTEIN TYROSINE KINASE; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; FEMALE; GENE MUTATION; HUMAN; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; MALE; MYELODYSPLASTIC SYNDROME; PANCREAS CANCER; PRIORITY JOURNAL; PROMYELOCYTE; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; TESTIS CANCER; ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW CELL; CHROMOSOME ABERRATION; COMPARATIVE STUDY; FLOW CYTOMETRY; GENETICS; GRANULOCYTE PRECURSOR; IMMUNOCOMPROMISED PATIENT; METABOLISM; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; MUTATION; PATHOLOGY; PROGNOSIS; SECOND CANCER; SURVIVAL RATE; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BONE MARROW CELLS; CHROMOSOME ABERRATIONS; COMBINED MODALITY THERAPY; FEMALE; FLOW CYTOMETRY; GRANULOCYTE PRECURSOR CELLS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MARYLAND; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; PROTEIN-TYROSINE KINASES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84859237502     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPE0MV0YTWLUUE     Document Type: Article

References (28)

1. Kakizuka A, Miller WH Jr., Umesono K, et al.Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 1991;66:663-674. (Pubitemid 121001702)
2. Degos L, Dombret H, Chomienne C, et al.All-trans -retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood. 1995;85:2643-2653.
3. Kayser S, Dohner K, Krauter J, et al.The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011;117:2137-2145.
4. Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol. 2008;35:418-429.
5. Borthakur G, Estey AE. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome. Curr Oncol Rep. 2007;9:373-377. (Pubitemid 47377068)
6. Weinberg OK, Seetharam M, Ren L, et al.Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood. 2009;113:1906-1908.
7. Miesner M, Haferlach C, Bacher U, et al.Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC). Blood. 2010;116:2742-2751.
8. Mauritzson N, Albin M, Rylander L, et al.Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia. 2002;16:2366-2378. (Pubitemid 36067289)
9. Rizzieri DA, O'Brien JA, Broadwater G, et al.Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia. Cancer. 2009;115:2922-2929.
10. Bello C, Yu D, Komrokji RS, et al.Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer. 2011;117:1463-1469.
11. Olney HJ, Mitelman F, Johansson B, et al.Unique balanced chromosome abnormalities in treatment-related myelodysplastic syndromes and acute myeloid leukemia: report from an international workshop. Genes Chromosomes Cancer. 2002;33:413-423. (Pubitemid 34208802)
12. Vardiman JW, Arber DA, Brunning RD, et al.Therapy-related myeloid neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al. eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
13. Andersen MK, Larson RA, Mauritzson N, et al.Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer. 2002;33:395-400. (Pubitemid 34208800)
14. Pollicardo N, O'Brien S, Estey EH, et al.Secondary acute promyelocytic leukemia: characteristics and prognosis of 14 patients from a single institution. Leukemia. 1996;10:27-31.
15. Beaumont M, Sanz M, Carli PM, et al.Therapy-related acute promyelocytic leukemia. J Clin Oncol. 2003;21:2123-2137. (Pubitemid 46606361)
16. Detourmignies L, Castaigne S, Stoppa AM, et al.Therapy-related acute promyelocytic leukemia: a report on 16 cases. J Clin Oncol. 1992;10:1430-1435. (Pubitemid 23059926)
17. Shih LY, Kuo MC, Liang DC, et al.Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia. Cancer. 2003;98:1206-1216.
18. Callens C, Chevret S, Cayuela JM, et al.Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. Leukemia. 2005;19:1153-1160. (Pubitemid 40945998)
19. Hayden PJ, O'Connell NM, O'Brien DA, et al.The value of autofluorescence as a diagnostic feature of acute promyelocytic leukemia. Haematologica. 2006;91:417-418.
20. Exner M, Thalhammer R, Kapiotis S, et al.The "typical" immunophenotype of acute promyelocytic leukemia (APL-M3): does it prove true for the M3-variant? Cytometry. 2000;42:106-109. (Pubitemid 30241576)
21. Ammatuna E, Montesinos P, Hasan SK, et al.Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis. Haematologica. 2011;96:621-625.
22. Pascual AM, Téllez N, Boscá I, et al.Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Mult Scler. 2009;15:1303-1310.
23. Montesinos P, Rayon C, Vellenga E, et al.Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood. 2011;117:1799-1805.
24. Ferrara F, Morabito F, Martino B, et al.CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans -retinoic acid and chemotherapy. J Clin Oncol. 2000;18:1295-1300. (Pubitemid 30159848)
25. De BS, Chevret S, Sanz M, et al.Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol. 2000;111:801-806. (Pubitemid 32098918)
26. Beitinjaneh A, Jang S, Roukoz H, et al.Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review. Leuk Res. 2010;34:831-836.
27. Chillon MC, Santamaria C, Garcia-Sanz R, et al.Long FLT3 internal tandem duplications and reduced PML-RARalpha expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients. Haematologica. 2010;95:745-751.
28. Lai CP, Chang CC, Chung CY, et al.Unusual acute promyelocytic leukemia following de novo renal transplant: case report and literature review. Clin Nephrol. 2011;75(suppl 1):27-31.